Welcome to our dedicated page for Immix Biopharma news (Ticker: IMMX), a resource for investors and traders seeking the latest updates and insights on Immix Biopharma stock.
Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nexcella, a subsidiary of Immix Biopharma (NASDAQ: IMMX), reported promising clinical data from its Phase 1b/2 NEXICART-1 trial (NCT04720313) for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The data indicated a 92% overall response rate in multiple myeloma and a 100% response rate in AL amyloidosis patients, with median progression-free survival of 12.3 months. These results were presented at the EBMT 49th Annual Meeting in Paris. Nexcella aims to submit a BLA for FDA approval in both conditions after treating 100 patients for multiple myeloma and 30-40 for AL amyloidosis. The markets for multiple myeloma and AL amyloidosis are projected to expand significantly by 2027 and 2025, respectively, presenting substantial commercial opportunities for NXC-201.
Nexcella Inc., a subsidiary of Immix Biopharma (NASDAQ: IMMX), announced the presentation of updated clinical data for NXC-201, a CAR-T therapy for multiple myeloma and AL amyloidosis, at the 49th annual meeting of the European Society for Blood and Marrow Transplantation in Paris from April 23-26, 2023.
The updated data show a 90% overall response rate and a 59% complete response rate in relapsed/refractory multiple myeloma. Notably, NXC-201 achieved a 100% hematologic and organ response rate in AL amyloidosis patients. These results reflect the potential of NXC-201 as the first outpatient CAR-T therapy for these conditions.
Nexcella, a subsidiary of Immix Biopharma, Inc. (NASDAQ: IMMX), announced the publication of an editorial in Haematologica discussing the safety and efficacy of their BCMA CAR-T cell therapy, NXC-201. The therapy shows a 75% overall response rate, comparable to existing FDA-approved therapies. As of March 2023, 58 patients have been treated, primarily for multiple myeloma. The multiple myeloma market, valued at $13.9 billion in 2017, is projected to reach $28.7 billion by 2027. NXC-201 is under investigation for relapsed or refractory multiple myeloma and AL amyloidosis, demonstrating a favorable safety profile with outpatient treatment potential.
Nexcella, a subsidiary of Immix Biopharma (IMMX), announced promising results for NXC-201, a CAR-T therapy targeting relapsed/refractory multiple myeloma and AL amyloidosis. The treatment has shown a 100% complete hematologic response and a 100% organ response rate in 8 AL amyloidosis patients. A total of 58 patients have been treated, with notable safety data confirming outpatient treatment potential. The $13.9 billion multiple myeloma market is projected to grow to $28.7 billion by 2027, while the amyloidosis market is expected to reach $6 billion by 2025, according to industry research.